This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Invest Like Warren Buffett with These Stocks & ETF
by Neena Mishra
Moat investing, popularized by Buffett, looks for attractively priced companies with sustainable competitive advantages.
PFE or NVO: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PFE vs. NVO: Which Stock Is the Better Value Option?
Invest Like Warren Buffett with These Stocks & ETF
by Neena Mishra
Moat investing, popularized by Buffett, looks for attractively priced companies with sustainable competitive advantages.
Company News For Oct 11, 2018
by Zacks Equity Research
Companies in the news are: CPB, FAST, MYGN, PFE and SHLD
Molecular Diagnostic Market Gains Momentum: 3 Stocks in Focus
by Sweta Jaiswal
Rising incidence of infectious diseases and increasing acceptance of companion diagnostics are driving the molecular diagnostics market.
J&J's Stelara Succeeds in Phase III Ulcerative Colitis Study
by Zacks Equity Research
J&J's (JNJ) Stelara induces clinical remission and response in ulcerative colitis patients who had failed prior therapy, per data from a phase III study.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Sweta Killa
Sector ETF report for PPH
The Zacks Analyst Blog Highlights: Apple, Microsoft, Pfizer, Caterpillar and ConocoPhillips
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Microsoft, Pfizer, Caterpillar and ConocoPhillips
Top Stock Reports for Apple, Microsoft & Pfizer
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Microsoft (MSFT) and Pfizer (PFE).
Pharma Stock Roundup: PFE to Get New CEO, LLY Presents Impressive Diabetes Data
by Zacks Equity Research
Pfizer (PFE) CEO, Ian Read to be replaced by present chief operating officer. Pipeline updates from Lilly (LLY), Novartis (NVS), J&J (JNJ) and others.
Dow 30 Stock Roundup: Boeing Wins $9.2B Pilot Training Deal, Intel Keeps '18 View
by Swarup Gupta
The index advanced strongly this week before suffering a sharp decline on Thursday.
Top Performing ETFs of the Third Quarter
by Neena Mishra
Healthcare emerged as the new leader in Q3. Here is what investors need to know about best performing sectors and ETFs.
5 Reasons Why Investors Should Bet on Pfizer (PFE) Stock
by Zacks Equity Research
Here are five aspects that investors may consider while investing in Pfizer's (PFE) stock.
J&J's Phase III Data Shows Switch to its HIV Drug Beneficial
by Zacks Equity Research
Data from the 96-week long phase III EMERALD study shows that switching to J&J's (JNJ) Symtuza maintains high virologic suppression.
Novartis, Boston Pharma Ink Deal for 3 Anti-Infective Drugs
by Zacks Equity Research
Novartis inks licensing deal with Boston Pharma for the development of three novel anti-infective drug candidates.
Pfizer's CEO Ian Read to Step Down Next Year, COO to Succeed
by Zacks Equity Research
Pfizer's (PFE) CEO Ian Read to step down from his role and current COO Albert Bourla to take up the vacant position beginning 2019.
Is Pfizer (PFE) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (PFE) Outperforming Other Medical Stocks This Year?
Why Pfizer (PFE) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Pfizer (PFE) have what it takes? Let's find out.
QIAGEN's FDA Nod for Expanded EGFR Test Use Widens Suite
by Zacks Equity Research
QIAGEN (QGEN) continues to expand test menu; latest FDA approval to boost portfolio.
Pfizer (PFE) Stock Moves 0.27%: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $44.07, marking a +0.27% move from the previous day.
Pfizer's (PFE) Lung Cancer Drug Vizimpro Gets FDA Approval
by Zacks Equity Research
The FDA approves Pfizer's (PFE) Vizimpro for first-line treatment of locally advanced or metastatic non-small cell lung cancer in patients with epidermal growth factor receptor activating mutations.
Pharma Stock Roundup: PFE, LLY Get Approval for New Drugs, Novartis to Cut Jobs
by Zacks Equity Research
FDA grants approval to Lilly's (LLY) Emgality for migraine and Pfizer's (PFE) Vizimpro for an advanced lung cancer indication. Novartis (NVS) to cut more than 2,000 jobs in Switzerland and U.K
Women Health a Prime Concern Worldwide: 3 Stocks in Focus
by Zacks Equity Research
Women health care gradually gaining importance globally, investors might keep an eye on a few stocks.
AstraZeneca's Imfinzi Gets EU Nod for Early-Stage Lung Cancer
by Zacks Equity Research
AstraZeneca's (AZN) PD-L1 inhibitor Imfinzi gets approval in EU for an early-stage lung cancer indication.
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $44.06, marking a +0.71% move from the previous day.